Business Wire

  1. Horizon Healthcare Services, Inc. Turns To Kentmere Healthcare Consulting Corporation To Expand Outpatient Laboratory Network
    12/12/2018

    Kentmere Healthcare Consulting Corporation of Wilmington, Del. said recently that Horizon Healthcare Services, Inc., New Jersey’s oldest and largest health insurer, utilized its services to evaluate, analyze and optimize their outpatient laboratory provider network

  2. Bay Labs, Edwards Lifesciences Collaborate On AI Software To Improve Heart Disease Detection
    12/10/2018

    Bay Labs, a medical technology company at the forefront of applying artificial intelligence (AI) to cardiovascular imaging, announced recently a collaboration with Edwards Lifesciences focused on improving the detection of heart disease.

  3. PPD Expands GMP Lab Testing Capabilities For Biologics
    12/6/2018

    Pharmaceutical Product Development, LLC (PPD) is adding gene and cell therapy analytical testing to its GMP (good manufacturing practices) laboratory in Athlone, Ireland, to support the pharmaceutical industry’s growing need for biologics testing. The enhancements in PPD® Laboratories’ Athlone location complement the ongoing capacity and capability expansions at its flagship GMP lab in Middleton, Wisconsin, enabling the company to expand the global reach of its industry-leading biologics testing services. This press release features multimedia.

  4. Know Labs Announces Laboratory Comparison Tests Of Its UBAND Non-Invasive Blood Glucose Technology And Abbott Labs FreeStyle Libre
    12/6/2018

    Know Labs, Inc. (OTCQB: KNWN), a provider of identification, authentication and diagnostic solutions, released today a video overview of comparison tests of the Company’s invention of its UBAND™ wearable to detect blood glucose non-invasively and Abbott Labs FreeStyle Libre. In the video Company CEO Phil Bosua discusses the breakthrough and highlights a comparison of the Know Labs UBAND Bio-RFID™ technology with an industry-leading continuous glucose monitor from Abbott Laboratories (NYSE: ABT). The transcript of

  5. CSI Laboratories Advances Precision In Cancer Diagnostics By Partnering With Dr. Maher Albitar Of Genomics Testing Cooperative (GTC)
    12/5/2018

    CSI Laboratories, nationally renowned for its quality cancer diagnostics, recently announces its partnership with Genomic Testing Cooperative (GTC) in order to provide a new level of Next Generation Sequencing to the market

  6. China National Medical Products Administration Approves Descovy (Emtricitabine, Tenofovir Alafenamide) For The Treatment Of HIV-1 Infection
    12/4/2018

    Gilead Sciences, Inc. recently announced that the China National Medical Products Administration (NMPA) has approved Descovy (emtricitabine 200 mg/tenofovir alafenamide 10 mg and emtricitabine 200 mg/tenofovir alafenamide 25 mg, F/TAF), a fixed-dose combination for the treatment of HIV

  7. Asuragen Launches Assay To Aid In The Diagnosis Of Myotonic Dystrophy Type I (DM1)
    12/4/2018

    Asuragen, Inc., a molecular diagnostics company delivering easy-to-use products for complex testing in genetics and oncology, recently announced the CE marking and launch of the AmplideX DM1 Dx Kit, which simplifies the analysis of repeat expansions within the DMPK gene and is intended to aid in the diagnosis of Myotonic Dystrophy Type I (DM1), also known as Steinert’s Disease

  8. Bio-Rad Quality Controls Now Available For Multiple Abbott Clinical Diagnostics Platforms
    12/3/2018

    Bio-Rad Laboratories, Inc., a global leader of life science research and clinical diagnostic products, recently announced expanded global access of the company’s quality controls across multiple Abbott clinical diagnostics platforms that now includes the Abbott Alinity ci-series instruments

  9. RDx BioScience Lauds Passage Of H.R.6 Support Act To Fight Opioid Epidemic: Emphasizes Need For Prescriber Education, Drug Testing And Pain Management
    11/28/2018

    With the passage of new federal opioid legislation to help prevent opioid misuse and abuse, better inform patients in pain management, and set up systems for safe storage and disposal of unused opioid prescriptions, RDx BioScience emphasizes the importance of prescriber education, increased access to drug testing programs, and heightened vigilance regarding New Psychoactive Substances (NPS) – synthetic, illicit drugs – that are hitting the street and threatening lives

  10. Two Pore Guys Receives $2.8M Grant To Develop Sensitive, Low-Cost Molecular Diagnostic Tests For Tuberculosis
    11/19/2018

    Two Pore Guys, Inc. (2PG) recently announced that the company has received a $2.8M grant from the Bill & Melinda Gates Foundationto develop sensitive, low-cost molecular diagnostic tests for tuberculosis (TB) using its solid-state nanopore technology